ALL Metrics
-
Views
-
Downloads
Get PDF
Get XML
Cite
Export
Track
Review

Recent advances in the management of ventricular tachyarrhythmias

[version 1; peer review: 2 approved]
PUBLISHED 29 Jun 2017
Author details Author details
OPEN PEER REVIEW
REVIEWER STATUS

Abstract

Ventricular arrhythmias are an important cause of cardiovascular morbidity and mortality, particularly in those with structural heart disease, inherited cardiomyopathies, and channelopathies. The goals of ventricular arrhythmia management include symptom relief, improving quality of life, reducing implantable cardioverter defibrillator shocks, preventing deterioration of left ventricular function, reducing risk of arrhythmic death, and potentially improving overall survival. Guideline-directed medical therapy and implantable cardioverter defibrillator implantation remain the mainstay of therapy to prevent sudden cardiac death in patients with ventricular arrhythmias in the setting of structural heart disease. Recent advances in imaging modalities and commercial availability of genetic testing panels have enhanced our mechanistic understanding of the disease processes and, along with significant progress in catheter-based ablative therapies, have enabled a tailored and more effective management of drug-refractory ventricular arrhythmias. Several gaps in our knowledge remain and require further research. In this article, we review the recent advances in the diagnosis and management of ventricular arrhythmias.

Keywords

Ventricular Arrhythmias, cardiomyopathy, catheter ablation, implantable cardioverter-defibrillator

Introduction

Sudden cardiac death claims 350,000 to 400,000 lives annually in the US1. Ventricular fibrillation (VF) or pulseless ventricular tachycardia (VT) accounts for 25 to 36% of witnessed cardiac arrests at home and 38 to 79% of witnessed cardiac arrests in public2. Ventricular arrhythmias (VAs) represent a broad spectrum spanning single ectopic beats to sustained VT and VF. These arrhythmias encompass clinical conditions ranging from benign to life threatening. Sustained VAs are mostly associated with structural or ischemic heart disease (60 to 80%) followed by channelopathies and idiopathic VAs (VA in the absence of structural heart disease)3,4. Although life-threatening VAs are greatest in those with known coronary artery disease, myocardial infarction, and depressed ejection fraction, a considerable number of patients with non-ischemic cardiomyopathy (NICM) experience fatal events due to VT or VF as well5.

Different forms of VAs can coexist in the same patient, can be isolated or frequent, and have differing mechanisms. Premature ventricular contractions are the most common and are generally considered benign. Non-sustained VT is at least three consecutive ventricular beats at a rate of at least 100 beats per minute; if VT exceeds 30 seconds or is hemodynamically unstable, it is considered “sustained”. VT can be regular or irregular in rate and morphology. Sustained monomorphic VT has the same activation sequence from beat to beat and generally occurs because of a stable re-entry circuit in patients with structural heart disease or because of automaticity in idiopathic VTs. The 12-lead electrocardiogram (ECG) provides an approximation of the exit site. On the other hand, polymorphic VT that often degenerates into VF is more often seen in acute myocardial ischemia or infarction as well as with several genetically mediated syndromes6.

The goals of management of VAs include symptom relief (including syncope, worsening heart failure, and ischemic chest pain), improving quality of life, reducing implantable cardioverter defibrillator (ICD) shocks, preventing deterioration of left ventricular function, reducing risk of arrhythmic death, and improving overall survival710. Treatment of VAs should take into account the underlying medical conditions, the cardiac disorders, the presence of heart failure, the cause for the arrhythmias, consequences of the VAs, and the risks and benefits of the therapeutic pharmacological or invasive strategy6,8,9.

ICDs are the mainstay of therapy to reduce the risk of sudden cardiac death due to VT and VF. Despite the mortality benefit gained from ICD therapy, electrical shocks from the device as well as unopposed and unnecessary right ventricular pacing should be monitored for and appropriately addressed7,1113. According to current data, both anti-arrhythmic drugs and catheter ablation may reduce the recurrence of VAs without offering any survival benefit10. Recurrent ventricular tachyarrhythmias and ICD shocks are the major indication for anti-arrhythmic drug therapy, but these medications can also be pro-arrhythmic13. Catheter ablation has evolved as a promising therapy to reduce the risk of VT recurrence; it is superior to medical therapy alone, according to clinical trials1416. Despite improved mechanistic understanding and progress in catheter ablation technology that has led to effective treatment of focal and idiopathic VT, the long-term success rates for VT ablation remain modest in both ischemic and non-ischemic cardiomyopathies17.

Considerable research and clinical effort in recent years have been focused on the development of diagnostic modalities and imaging tools to identify the arrhythmogenic substrate responsible for VT (focal or scar), genetic screening for markers of channelopathies, and superior mapping and ablation technologies. These advances have allowed us to tailor our approach to VA management on the basis of the underlying etiology with higher efficacy6,8,9.

In this review, we aim to provide an update on the newer advances in the management of VAs.

Update on diagnostic and non-invasive imaging modalities

For over 100 years, cardiologists relied on the ECG, monitoring strategies, and limited intracardiac electrodes to diagnose VAs. With mechanisms of VT now better defined in structural heart disease, non-invasive imaging modalities—including echocardiography, cardiac computed tomography (CT), cardiac magnetic resonance imaging (MRI) (CMR), and nuclear studies—have become an integral part of the diagnostic and management strategy. The information derived from these tests not only is important to identify those with structural heart disease, assess left and right ventricular function, and risk-stratify those at highest risk of inducible VT/VF on the basis of scar size in order to select the patients who would derive the most benefit from an ICD but also serves as a guide for planning ablation procedures8,18,19. The 2015 European Society of Cardiology Guidelines have extended a class IIa recommendation to perform CMR or CT in patients where echocardiography fails to provide accurate assessment of ventricular function or underlying structural changes that may be arrhythmogenic, such as the scar size, distribution, and transmurality8.

Although there are no large randomized controlled trials, multiple small studies have reported a potential benefit of obtaining pre-procedural imaging such as delayed enhancement CMR (DE-MRI) and incorporating the information into intracardiac mapping systems20. Piers et al.21 described the characteristics of critical isthmus sites in 44 patients with ischemic cardiomyopathy and NICM undergoing VT ablation with pre-procedural CMR. The authors found the critical VT isthmus sites to be in close proximity to areas of higher (>75%) scar transmurality and scar border zones as noted in CMR.

Contrast-enhanced MRI- and CT-derived scar data have been shown to correlate well with electroanatomic mapping (EAM) reconstructions. In a recent study by Esposito et al.22, CT with delayed enhancement provided a detailed three-dimensional (3D) scar characterization with good sensitivity (76%) and specificity (86%) and a very high negative predictive value (95%) when correlated with voltage on EAM. Whereas EAM may be unable to quantify the non-transmural parts of the scar, information obtained from pre-procedural CMR may help in these instances.

Substrate characterization with CMR is also very useful in hypertrophic cardiomyopathy (HCM), arrhythmogenic right ventricular dysplasia (ARVD), and acquired immunological and inflammatory conditions (for example, sarcoidosis)2228. A minority of patients with sustained left bundle branch block and inferior axis morphology VT, resembling idiopathic outflow tract VT, may have early concealed ARVD. CMR can help differentiate true idiopathic VT from early-stage ARVD or sarcoidosis and change the clinical approach for these patients29. CMR may be of particular value in those with abnormal resting ECG (for example, right precordial T wave inversion in V1–V3).

Contrast CT has the added advantage of providing good visualization of coronary arteries. Lipomatous metaplasia (myocardial fat deposition) along with fibrosis in areas of chronic myocardial infarction has been observed in patients with ischemic heart disease on contrast CT and has been associated with fractionated electrograms and critical VT circuits30. In patients with VT due to a local (myocarditis) or systemic (for example, sarcoidosis) inflammatory condition, fluorine-18 fluoro-2-deoxyglucose (18-FDG) positron emission tomography (PET/CT) can identify patients who may benefit from early immunosuppressive therapy versus catheter ablation31.

The future of non-invasive mapping of VAs will focus on the creation of image-based simulation to estimate ablation targets in VAs, integration of multi-lead electrocardiography to construct computerized activation maps, and endo-epicardial and perhaps also mid-myocardial signal-intensity mapping that will identify the pathological substrates and VT exit sites which can be targeted more efficaciously3234.

Advances in channelopathies and inherited cardiomyopathies

Up to half of the families of sudden cardiac arrest victims below 50 years of age are carriers of cardiac genetic channelopathies or hereditary cardiomyopathies. The 2015 Expert Consensus Statement from the Heart Rhythm Society recommends that patients and first-degree relatives with diagnosed or suspected inherited cardiovascular disease as a potential cause of sudden cardiac arrest be evaluated in a dedicated clinic with appropriately trained staff (class I)9,35.

Extended molecular gene panels now can be performed at appropriate centers at a low cost, allowing early identification of a channelopathy or inherited cardiomyopathy. This, in turn, allows risk stratification of sudden cardiac death and introduction of appropriately timed therapy (lifestyle changes, pharmacologic therapy versus ICD implantation or catheter ablation or both (Table 1)9,3537.

Table 1. Heart Rhythm Society/European Society of Cardiology recommendations for the diagnosis and treatment of genetic arrhythmia syndrome and inherited cardiomyopathies.

Genetic
arrhythmia
syndrome
Associated gene and ion channel
affected
Recommendations for diagnosisRecommendations for treatment
LQTS   •   Associated with mutations in at
least 15 genes
   •   Three main genes: KCNQ1
(LQTS1), KNCH2 (LQTS2), and
SCN5A (LQTS3) (75% of cases)
   •   IKr (LQTS1), IKs (LQTS2), INa
(LQTS3), IK1 (LQTS7), and ICa-L
(LQTS8)
   •   AD LQTS with QT prolongation
alone (Romano-Ward syndrome)
LQTS 1–6
   •   AD LQTS7 (Anderson-Tawil
syndrome): facial dysmorphism
and hyper/hypokalemic periodic
paralysis
   •   AD LQTS8 (Timothy
syndrome) prolonged QT,
facial dysmorphism, cardiac
malformations, and autism
   •   Autosomal recessive LQTS
(Jervell and Lange-Nielson
syndrome) extremely prolonged
QT interval with congenital
deafness
   •   QTc ≥ 480 ms in repeated 12-
lead ECGs or LQTS risk score >3
(class I)
   •   Confirmed pathogenic LQTS
mutations (class I)
   •   QTc ≥ 460 ms with unexplained
syncopal episode in the absence of secondary
causes of QT
prolongation
   •   Avoid QT prolonging agents, correct
electrolytes, and avoid genotype-
specific triggers (for example,
strenuous exercise for LQTS1 and
loud noise for LQTS2)
   •   BBs are recommended for patients
with clinical diagnosis (class I) and
carriers of causative mutation and
normal QTc (class IIa)
   •   ICD should be implanted in patients
with prior SCA (class I), syncope
and/or VT while on adequately
dosed BBs (class IIa) or considered
in addition to BBs in asymptomatic
carriers of KCNH2 or SCN5A
mutations and a QTc > 500 ms
   •   LCSD can be attempted in patients
with ineffective or poorly tolerated
BB therapy, contraindication to ICD,
or incessant VT, multiple ICD shocks
(class IIa)
   •   Sodium channel blockers
(Mexiletine, Flecainide, Ranolazine)
may be used as adjunctive therapy
in LQTS3 with QTc >500 ms
   •   Invasive EPS and PVS is not
recommended for risk stratification (class III)
SQTS   •   KCNH2 (SQT1), KCNQ1 (SQT2),
and KCNJ2 (SQT3)
   •   IKr (SQT1), IKs (SQT2), and IK1
(SQT3)
   •   QTc ≤ 340 ms on ECG (class I)
   •   QTc ≤ 360 ms and confirmed
pathogenic mutation, family
history of SQTS, family history
of SCD <40 years, survival from
VT/VF in the absence of heart
disease (class IIa)
   •   ICD implant is recommended in
patients with spontaneous sustained
VT or SCA (class I)
   •   Quinidine or sotalol are
recommended in patients who
refuse or have a contraindication to
ICD or in asymptomatic patients with
SQTS and a family history of SCD
(class IIb)
   •   Invasive EPS and PVS are not
recommended for risk stratification
(class III).
BrS   •   Inherited AD
   •   12 genetic mutations identified
   •   SCN5A and CACN1Ac (account for
more than 5% of positively
genotyped patients)
   •   Genetic screening does not affect
treatment or prognosis.
   •   ST-segment elevation with type
1 morphology ≥2 mm elevation
in one or more right precordial
leads V1 and/or V2 positioned
in the second, third, or fourth
intercostal space, occurring either
spontaneously or after provocative
drug test with intravenous
administration of sodium channel
blockers such as ajmaline,
flecainide, and procainamide
(class I)
   •   Lifestyle changes: Patients should
avoid drugs that may induce
ST elevation, excessive alcohol
consumption, and seek prompt
treatment of fever (class I)
   •   ICD implantation is recommended in
survivors of SCA and/or spontaneous
sustained VT or both (class I) or in
patients with spontaneous Brugada
pattern and history of syncope
(class IIa) or patients with diagnosis
of BrS who develop VF during PVS with
two or three extra stimuli at two sites
(class IIb)
   •   Quinidine or isoproterenol to be
considered in electrical storm (class
IIa). Quinidine should be considered
in patients with BrS who refuse
or have a contraindication to ICD
implantation (class IIa)
   •   Catheter ablation may be considered
in patients with repeated ICD shocks
and electrical storm (class IIb).
ERS   •   Polygenic
   •   Role of genetic screening is not
clear
   •   IK-ATP (ERS1, 5), ICa (ERS2-4),
and INa (ERS6)
   •   No clear familial transmission
   •   Asymptomatic early repolarization
pattern is common in general
population.
   •   ERS diagnosed only in patients
with a pattern and documented
idiopathic VF or polymorphic VT
   •   Insufficient evidence to make
definitive recommendations
CPVT   •   Dominant variant: ryanodine
receptor gene (RyR2)
   •   Rare recessive variant: cardiac
calsequestrin gene (CASQ2)
   •   Other genes: KCNJ2, Ank2,
TRDN, and CALM1
   •   Induction of bidirectional or
polymorphic VT in the presence of
structurally normal heart and ECG
(class I)
   •   Diagnosed carriers of a
pathogenic mutation on genetic
screening (RyR2 or CASQ2)
   •   Avoidance of competitive sports,
stress environments, and strenuous
exercise (class I)
   •   BBs recommended for all patients
(class I), genetically positive family
members of proband without
exercise induced VT (class IIa)
   •   Flecainide should be considered
in addition to BBs in patients with
recurrent syncope or VT or with
contraindication to ICD (class IIa)
or in patients with ICD to reduce
shocks (class IIa)
•   ICD and BBs and/or flecainide
in patients with SCA, recurrent
syncope, or polymorphic VT despite
optimal therapy (class I)
•   LCSD can be performed in CPVT
patients with recurrent syncope,
arrhythmia, recurrent ICD shocks
while on maximal therapy or who are
intolerant to medical therapy (class IIb)
   •   Invasive EPS with PVS is not
recommended for risk stratification
(class III).
HCM   •   AD
   •   10 genes encoding from proteins
in cardiac sarcomere
   •   Beta-myosin, troponin T and I,
alpha-tropomyosin, myosin light
chains, titin, alpha actin, alpha
myosin heavy chain, and muscle
LIM protein (MLP)
   •   Non-sarcomeric protein mutations
(storage disease) clinically similar
PRKAG2, LAMP2
   •   Commercially available genetic
testing
   •   Left ventricular hypertrophy
max wall thickness ≥15 mm,
asymmetric (>1.3:1), concomitant
obstructive pathology and
mitral regurgitation, diastolic
dysfunction, abnormal papillary
muscles on transthoracic
echocardiography or cardiac
magnetic resonance imaging
(class I)
   •   Genetic testing is recommended
in index patient and family
members (class I)
   •   Avoidance of competitive sports,
stress environments, and strenuous
exercise (class I)
   •   ICD in survivors of SCA or sustained
VT/VF causing syncope (class I)
   •   Risk stratification with HCM SCD
risk calculator (class I)
   •   BBs or calcium channel blockers
(class I) or disopyramide (class IIa)
to treat obstructive symptoms.
Guideline-directed medical therapy
for congestive heart failure (class IIa)
   •   Invasive EPS with PVS is not
recommended for risk stratification
of SCD (class III)

AD, autosomal dominant; BB, beta blocker; BrS, Brugada syndrome; CPVT, catecholaminergic polymorphic ventricular tachycardia; ECG, electrocardiogram; EPS, electrophysiologic study; ERS, early repolarization syndrome; HCM, hypertrophic cardiomyopathy; ICD, implantable cardioverter defibrillator; LQTS, long QT syndrome; LCSD left cervical sympathetic denervation; PVS, programmed ventricular stimulation; SCA, sudden cardiac arrest; SCD, sudden cardiac death; SQTS, short QT syndrome; VF, ventricular fibrillation; VT, ventricular tachycardia.

An important breakthrough in treating genetic arrhythmia syndromes has been the identification of a potential arrhythmic substrate located in the epicardial right ventricular outflow tract (RVOT) that may trigger VT/VF in some patients with Brugada syndrome. Epicardial 3D EAM has shown abnormal low voltage and fractionated late potentials clustered exclusively in the anterior RVOT epicardium. Ablation at these sites rendered VT/VF non-inducible in 78% and normalization of the Brugada ECG pattern (coved ST-elevations in V1 and V2) in 89%. A multicenter randomized study—Ablation in Brugada Syndrome for the Prevention of VF episodes (BRAVE Study)—is being planned and will assess long-term outcomes of catheter ablation in patients with Brugada syndrome38,39.

Medical management of ventricular tachycardia in structural heart disease: Will there be a realm beyond amiodarone therapy?

Pharmacologic therapy for preventing VAs has yielded disappointing results in recent years. Therapy has been limited because of variable efficacy, pro-arrhythmic effects, patient compliance, and adverse effects from long-term therapy. As adjuvant suppressive therapy in patients with ICDs, amiodarone and sotalol have been shown to reduce the rate of recurrent VT (71% and 15–44%, respectively) when compared with beta-blockers or placebo40. Current guidelines recommend pharmacologic therapy (amiodarone or sotalol) with or without adjunctive catheter ablation to prevent VT/VF recurrence and reducing ICD shocks8,16.

Intravenous amiodarone and sodium channel blockers (lidocaine and procainamide) remain the preferred drug regimen in the acute setting; however, more recently, intravenous sotalol has been shown to terminate sustained VT acutely with a higher efficacy versus lidocaine41. Neither amiodarone nor lidocaine, however, has been shown to improve survival or neurologic outcomes in patients with pulseless VT/VF and out-of-hospital cardiac arrest42. In the first prospective randomized study comparing intravenous procainamide and amiodarone in the acute treatment of hemodynamically tolerated wide complex tachycardia (VAs), procainamide was shown to be more efficacious in tachycardia termination (67% versus 38%) and was associated with fewer major cardiovascular events (9% versus 41%). The effect was consistently observed even in those with structural heart disease as well as when adjusted for age and sex. Although this study had a limited number of patients and was not blinded, it still points to the efficacy and safety of intravenous procainamide in the acute treatment of VT43.

Investigators of the VANISH trial showed an improved composite primary outcome of death, VT storm, or appropriate ICD shocks among patients undergoing catheter ablation versus escalation of anti-arrhythmic drug therapy (amiodarone or mexiletine or both) but with no significant difference between groups in terms of mortality44. In a recent meta-analysis comparing the effectiveness of anti-arrhythmic drugs versus catheter ablation for preventing recurrent VT in patients with ICDs, there was no significant difference between the two treatment modalities (odds ratio (OR) 0.58, 95% confidence interval (CI) 0.26–1.2, P = 0.17) in terms of risk reduction of VT as well as all-cause mortality (OR 0.58, 95% CI 0.24–1.24, P = 0.23)10. To avoid potential long-term adverse effects and reduce mortality, amiodarone may be safely reduced or discontinued after successful VT ablation without an increase in VT recurrence45.

Nifekalant, a pure potassium channel blocker that has been approved for use in Japan for VT since 1999, has not been shown to be superior to amiodarone in treating out-of-hospital cardiac arrest or shock-resistant sustained VT/VF46,47. Azimilide, another class III agent (not approved in the US), has been shown to reduce VAs and appropriate ICD shocks in patients with cardiomyopathies, according to data from the SHIELD trial48.

Development of efficacious anti-arrhythmic drugs for VAs with a limited adverse-effect profile continues to be a challenge.

What lies in the future for implantable device therapy

Next to guideline-directed medical therapy, ICDs can reduce the risk of sudden cardiac death according to several randomized controlled trials for secondary prevention in both ischemic cardiomyopathy and NICM11. For primary prevention of sudden cardiac death, particularly in NICM, the benefit from ICD has been modest primarily because of a lower rate of spontaneous VT/VF. The DANISH investigators49 showed no significant overall mortality benefit from primary prevention ICD implantation in patients with NICM and symptomatic heart failure. Importantly, this observation seems to be age-dependent as patients younger than 59 years derive significant benefit from the ICD.

Intravascular lead-related complications and inappropriate shocks are of particular significance in young patients with channelopathies and syndromes who are also at high risk for fatal VAs. ICD arrhythmia detection and programming algorithms have been refined over time to include higher minimum cutoff rates, extended detection time for VT, anti-tachycardia pacing, and morphology discriminators to minimize the risk of inappropriate shocks11,50.

The development of an entirely subcutaneous ICD (S-ICD) system with efficacy similar to that of conventional ICD in terminating VT/VF has been a major advance in device technology51,52. Although randomized comparative data are not yet available, pooled data from the EFFORTLESS and IDE trials have shown the S-ICD to be a safe and effective alternative to conventional transvenous ICDs—especially in younger patients with HCM, genetic channelopathies, and adult complex congenital heart disease—as long as there is no need for pacing5255. The rate of inappropriate shocks due to oversensing has been mitigated with the introduction of dual zone programming and algorithms to accommodate R- and T-wave amplitude variations56.

Two additional trials—PRAETORIAN and UNTOUCHED—will provide definitive data regarding a direct comparison of the S-ICD with a transvenous ICD system in terms of efficacy, appropriate and inappropriate shocks, and ICD-related complications57,58. An investigational percutaneous implantable intravascular defibrillator has also been developed that, compared with conventional ICD, has potentially lower complications and similar defibrillation thresholds59.

Invasive mapping and catheter ablation of ventricular tachycardia: Have we built the right tools to decode the substrate?

Catheter ablation guided by 3D EAM has emerged as an effective therapeutic option in patients with recurrent and sustained monomorphic VT, arrhythmia-induced cardiomyopathy, recurrent ICD shocks, intolerance to anti-arrhythmic medications, or a combination of these16. Catheter ablation of VT has a reported complication rate ranging from 5 to 7% according to different studies and has low periprocedural mortality and VT termination in up to 70% of cases16,60,61. The recurrence rate, however, remains high; 26 to 50% of patients experience recurrent VT during long-term follow-up17,62.

The success rate of catheter ablation for scar-mediated VT is higher in ischemic cardiomyopathy63. Substrate-guided VT ablation remains the preferred approach particularly when the arrhythmia is poorly tolerated. The VISTA trial showed an extensive substrate-based approach to be superior when compared with targeting clinical VT (15.5% VT recurrence in substrate-guided versus 48.3% in the clinical VT target group) in patients with ischemic cardiomyopathy64. The limitation in achieving higher success in NICM may be related to the more heterogeneous distribution of disease as well as transmurality and epicardial extension of scar62.

Kumar et al.65 reported better survival and low VT recurrence in patients without structural heart disease undergoing catheter ablation of VT compared with those with ischemic and non-ischemic cardiomyopathy. During long-term follow-up, the highest VA recurrence was seen in NICM (about 75% of those with NICM had at least one VA recurrence) but patients with ischemic cardiomyopathy had higher overall mortality.

Although we have limited data from randomized controlled trials and no proven mortality benefit yet for VT ablation in structural heart disease, recent studies do suggest that ablation results in improved quality of life, freedom from ICD shocks, and improved transplant-free survival. Tung et al.66 reported 1-year freedom from VT recurrence in up to 70% of patients with structural heart disease who underwent VT ablation (including 72% of patients with ischemic cardiomyopathy and 68% with NICM). Lack of recurrent VT translated as an improved transplant-free survival in this study66. Data from the THERMOCOOL VT trial looking at the long-term success of open irrigated radiofrequency (RF) catheter ablation of monomorphic VT associated with coronary artery disease showed reduced ICD shocks and VT episodes with improved quality of life at 6 months. At 3-year follow-up, non-recurrence resulted in decreased amiodarone use and hospitalizations67.

Other investigational and clinically tested techniques that could potentially improve substrate characterization, procedural outcomes and minimize complications include use of irrigated and contact force ablation catheters, incorporation of pre-procedural and intra-procedural imaging, ablation of deep myocardial substrate with bipolar RF ablation, transcoronary alcohol injection, coronary coil embolization, epicardial ablation, surgical cryoablation, and remote magnetic navigation, and stereotactic ablative radiotherapy (Table 2)6878. However, concrete data on the efficacy of these techniques is lacking and further studies are needed.

Table 2. Investigational modalities for ventricular tachycardia ablation and suggested clinical applications.

Innovative modalityInvestigators and initial reportsSalient features and possible benefits
MRI-guided stereotactic ablative radiotherapy
   •   For patients with VT who have failed
standard therapy
   •   Uses anatomic scar imaging: MRI or
SPECT or both with superimposed voltage
map to accurately delineate scar
Cuculich et al. - ENCORE-VT
phase I/II study83
Clinical trial: NCT02919618
Loo et al. Stereotactic Ablative
Radiotherapy (STAR)84
Maguire et al. - CyberHeart’s
Cardiac Arrhythmia Ablation85
Clinical trial: NCT02661048
   •   A rapid and totally non-invasive
technique
   •   Pre-clinical data suggest significant
reduction in VT burden (>50%) and
reduction in implantable cardioverter
defibrillator therapy (>85%).
   •   Clinical trials to determine the acute and
long-term safety and efficacy initiated
   •   Gap-free ablation can be performed
in short duration for medically frail
population
Infusion needle catheter ablation
   •   Infusion needle catheter ablation is being
studied for effectiveness in patients
who have failed standard RF ablation,
especially with deep mid-myocardial
substrate for VT
   •   Needle design allows for myocardial
penetration, infusion of heated saline and
RF energy delivery
   •   Pre- and peri-procedural imaging helps
guide the procedure (e.g; intracardiac
echocardiography)
Sapp et al.77
Stevenson et al. Intramural Needle
Ablation for Recurrent Ventricle
Tachycardia86
Clinical trial: NCT01791543
   •   A bipolar or quadripolar catheter
equipped with an extensible needle that
can project up to 12 mm beyond tip is
used
   •   Heated saline can be infused through tip
and side pores
   •   Flow rate of saline determines lesion size
   •   Large lesions can be created, does not
require scar/lesion maturity
Facilitated RF ablation using magnetically
directed nanoparticles
   •   Iron, carbon, or titanium nanoparticles are
delivered within heat-sensitive liposomes
   •   Iron nanoparticles used in imaging
considered safe
   •   Study in vivo porcine models
Nguyen et al.87   •   Nanoparticles have been shown to alter
tissue sensitivity to RF energy with a
potential to create deeper lesions
   •   Better tissue heating avoids “steam
pops”
MRI-based signal intensity mapping for epicardial
substrate
   •   The technique helps to identify epicardial
substrate for monomorphic VT with
contrast enhanced MRI
   •   Images can be correlated with standard
electroanatomical mapping
   •   Clinical data based on in vivo porcine
models available
Arenal et al.33   •   Epicardial VT substrate can be identified
by contrast-enhanced MRI-based signal
intensity mapping
   •   Patchy scar pattern may be associated
with VT inducibility
   •   Potential non-invasive imaging modality
to determine risk of inducible epicardial
VT prior to planned procedure
MIBG imaging to guide VT ablation
   •   MIBG has characteristics similar to
those of norepinephrine; it is taken up at
presynaptic neurons
   •   3D models with MIBG are created to
guide VT ablation
   •   A 15-patient feasibility study
   •   ADMIRE trial identified areas of cardiac
denervation and correlations with death,
heart failure, and VT/ventricular fibrillation
   •   MIBG (scan) US Food and Drug
Administration-approved 2013
Klein et al. - 3D MIBG Innervation
Maps to assess substrate and
successful ablation sites for VT88
Jacobson et al. ADMIRE-HF89
   •   MIBG innervation defects are larger than
scars created with bipolar voltage maps.
   •   In the pilot study 36% successful
ablative sites were located in areas
of abnormal innervation and normal
voltage
   •   Voltage maps do not necessarily
correlate with innervation maps.
   •   Innervation maps may help target
additional sites of VT ablation not
identified by EAM
Non-invasive high-resolution mapping and ECGI
   •   This technique offers single-beat
panoramic mapping
   •   Both endocardial and epicardial mapping
can be performed
Reports from 1998 to 2015; Rudy
et al.90,91
Zhang et al.92
   •   Non-invasive modality to provide
endocardial and epicardial substrate
information
   •   Information can be used to risk-stratify
patients and identify those at highest risk
of ventricular arrhythmia.
   •   ECGI has been shown to have a high
correlation with MRI and SPECT derived
scar
   •   Anti-arrhythmic drug exposure could
potentially affect amplitude and
fractionation.
Cardiac ripple mapping for slow conducting
channels
   •   A novel method to incorporate voltage and
activation data for EAM mapping
   •   High-density bipolar electrograms
collected
Luther et al.93
Jamil-Copley et al.94
   •   Allows for simultaneous visualization of
voltage and activation data incorporated
on 3D EAM
   •   Enables identification of slow
conduction channels within scar zones
in myocardium that may be potential
targets of VT ablation
   •   Target-specific approach can improve
efficacy of ablation.

3D, three-dimensional; EAM, electroanatomic map; ECGI, electrocardiographic imaging; MIBG, 123I-meta-iodobenzylguanidine; MRI, magnetic resonance imaging; RF, radiofrequency; SPECT, single-photon emission computed tomography; VT, ventricular tachycardia.

However, concrete data for their efficacy are lacking and more studies are needed. Epicardial substrate ablation has been identified as a potentially successful ablation strategy to eliminate VAs in select patients with ARVD and NICM and more recently in patients with Brugada syndrome38,39,79. In patients with incessant VT who have failed conventional and ablative therapy, left or bilateral cervical sympathectomy has been shown in observational studies to reduce VT recurrence, but larger studies are needed to establish the safety and efficacy of this procedure8082.

Conclusions

VAs encompass a broad range of clinical conditions ranging from benign to life-threatening. Sustained VAs are a major cause of morbidity and mortality in patients with structural heart disease. In addition to refinement and evolution of well-established therapies such as anti-arrhythmic drugs and ICDs, several major advances in the mechanistic, genetic, diagnostic, and therapeutic realms have furthered our understanding of the pathophysiology of ventricular tachyarrhythmias and helped fashion safer and more effective therapies particularly for drug-refractory VAs. Several gaps in our knowledge remain and require further research. Ultimately, successful short- and long-term management of VAs will likely integrate biological, pharmacologic, device-based, and ablative therapies.

Abbreviations

3D, three-dimensional; ARVD, arrhythmogenic right ventricular dysplasia; CI, confidence interval; CMR, cardiac magnetic resonance imaging; CT, computed tomography; EAM, electroanatomic mapping; ECG, electrocardiogram; HCM, hypertrophic cardiomyopathy; ICD, implantable cardioverter defibrillator; MRI, magnetic resonance imaging; NICM, non-ischemic cardiomyopathy; OR, odds ratio; RF, radiofrequency; RVOT, right ventricular outflow tract; S-ICD, subcutaneous ICD; VA, ventricular arrhythmia; VF, ventricular fibrillation; VT, ventricular tachycardia.

Comments on this article Comments (0)

Version 1
VERSION 1 PUBLISHED 29 Jun 2017
Comment
Author details Author details
Competing interests
Grant information
Copyright
Download
 
Export To
metrics
Views Downloads
F1000Research - -
PubMed Central
Data from PMC are received and updated monthly.
- -
Citations
CITE
how to cite this article
Batul SA, Olshansky B, Fisher JD and Gopinathannair R. Recent advances in the management of ventricular tachyarrhythmias [version 1; peer review: 2 approved]. F1000Research 2017, 6(F1000 Faculty Rev):1027 (https://doi.org/10.12688/f1000research.11202.1)
NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article.
track
receive updates on this article
Track an article to receive email alerts on any updates to this article.

Open Peer Review

Current Reviewer Status: ?
Key to Reviewer Statuses VIEW
ApprovedThe paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approvedFundamental flaws in the paper seriously undermine the findings and conclusions
Version 1
VERSION 1
PUBLISHED 29 Jun 2017
Views
0
Cite
Reviewer Report 29 Jun 2017
Pasquale Santangeli, Electrophysiology Section, Division of Cardiology, Hospital of the University of Pennsylvania, Philadelphia, USA 
Approved
VIEWS 0
I confirm that I have read this submission and believe that I have an ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Santangeli P. Reviewer Report For: Recent advances in the management of ventricular tachyarrhythmias [version 1; peer review: 2 approved]. F1000Research 2017, 6(F1000 Faculty Rev):1027 (https://doi.org/10.5256/f1000research.12086.r23771)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
Views
0
Cite
Reviewer Report 29 Jun 2017
Lars Eckardt, Division of Electrophysiology, Department of Cardiovascular Medicine, , University of Münster, Münster, Germany 
Approved
VIEWS 0
I confirm that I have read this submission and believe that I have an ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Eckardt L. Reviewer Report For: Recent advances in the management of ventricular tachyarrhythmias [version 1; peer review: 2 approved]. F1000Research 2017, 6(F1000 Faculty Rev):1027 (https://doi.org/10.5256/f1000research.12086.r23772)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.

Comments on this article Comments (0)

Version 1
VERSION 1 PUBLISHED 29 Jun 2017
Comment
Alongside their report, reviewers assign a status to the article:
Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions
Sign In
If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.

The email address should be the one you originally registered with F1000.

Email address not valid, please try again

You registered with F1000 via Google, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Google account password, please click here.

You registered with F1000 via Facebook, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Facebook account password, please click here.

Code not correct, please try again
Email us for further assistance.
Server error, please try again.